Umfang:
Online-Ressource (XVII, 373p. 71 illus., 36 illus. in color, digital)
ISBN:
9783642209109
Serie:
SpringerLink
Inhalt:
Roland E. Kontermann
Inhalt:
The concept of using bispecific antibodies for cancer therapy by retargeting immune effector cells was developed several years ago. Initial clinical studies were rather disappointing mainly due to low efficacy, severe side effects and the immunogenicity of the bispecific antibodies. The progress in antibody engineering finally led to the generation of new classes of bispecific antibodies lacking these obstacles. In addition, new applications were established, such as pre-targeting strategies in radioimmunotherapy and dual targeting approaches in order to improve binding, selectivity and effica
Anmerkung:
Includes bibliographical references and index
,
Bispecific Antibodies; Foreword; Index;
Weitere Ausg.:
ISBN 9783642209093
Weitere Ausg.:
Buchausg. u.d.T. Bispecific antibodies Berlin : Springer, 2011 ISBN 3642209092
Weitere Ausg.:
ISBN 9783642209093
Sprache:
Englisch
Fachgebiete:
Medizin
Schlagwort(e):
Monoklonaler bispezifischer Antikörper
;
Aufsatzsammlung
DOI:
10.1007/978-3-642-20910-9
URL:
Volltext
(lizenzpflichtig)
Mehr zum Autor:
Kontermann, Roland 1961-
